Repurposing Riluzole for Augmenting Brain-Derived Neuropathic Factor (BDNF) Levels and Cognitive Function in Patients Experiencing Cancer-Related Cognitive Impairment: An Interventional Pilot Clinical Trial
University of California, Irvine
Summary
This is a phase 2a, randomized, double-blinded, placebo-controlled pilot clinical trial determining the impact of riluzole therapy on circulating brain derived neuropathic factor (BDNF) levels of cancer survivors with cancer related cognitive impairment.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Female and male patients diagnosed with one of the following: 1. Breast cancer exposed to treatment including chemotherapy, radiotherapy, surgery and/or other breast cancer interventions 2. Non-breast cancer patients exposed to anthracyclines- or platinum-containing chemotherapy within the past 3 years 3. Non-breast cancer patients exposed to other anticancer therapies within the past 3 years * Washout from investigational interventions is up to the discretion of the Investigator. Concurrent participation in another intervention is allowable if judged by the Princ…
Interventions
- DrugRiluzole
Given PO
- DrugPlacebo
Given PO
Location
- Chao Family Comprehensive Cancer Center, University of California IrvineOrange, California